drug
estradiol ER
Marketedupdated 3mo agoby Noven Pharmaceuticals Inc
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 12 approved and 41 investigational indications.
all catalysts(22)
approval · 22
Apr 26, 1996
approval
$PFE26.79-0.04%
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Apr 18, 1997
approval
$PFE26.79-0.04%
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Dec 29, 1998
approval
ESTRADIOL — FDA approval
estradiol ER
→
Sep 24, 1999
approval
ESTRADIOL — FDA approval
estradiol ER
→
Nov 1, 1999
approval
ESTRADIOL — FDA approval
estradiol ER
→
Nov 1, 1999
approval
ESTRADIOL — FDA approval
estradiol ER
→
Jan 5, 2000
approval
$PFE26.79-0.04%
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
May 16, 2000
approval
$PFE26.79-0.04%
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Jul 24, 2001
approval
$PFE26.79-0.04%
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Aug 25, 2008
approval
$PFE26.79-0.04%
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
May 16, 2014
approval
$PFE26.79-0.04%
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Aug 12, 2014
approval
$PFE26.79-0.04%
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Sep 29, 2015
approval
$PFE26.79-0.04%
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Sep 29, 2015
approval
$PFE26.79-0.04%
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Nov 1, 2017
approval
$PFE26.79-0.04%
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Jan 4, 2019
approval
ESTRADIOL — FDA approval
estradiol ER
→
Jul 27, 2022
approval
$PFE26.79-0.04%
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Feb 15, 2024
approval
$PFE26.79-0.04%
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Feb 16, 2024
approval
ESTRADIOL — FDA approval
estradiol ER
→
Dec 8, 2025
approval
ESTRADIOL — FDA approval
estradiol ER
→
Jan 22, 2026
approval
ESTRADIOL — FDA approval
estradiol ER
→
Feb 12, 2026
approval
$PFE26.79-0.04%
ESTRING (ESTRADIOL) — FDA approval
estradiol ER
→
Trials studying estradiol ER
- phase1A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
- phase1Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
- phase1A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
- phase3The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial
- phase1A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives
- phase1A Study of Elenestinib in Healthy Adult Female Participants
- phase1Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
- phase4Menopausal HT for Women Living With HIV (HoT)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 10, 2028
~1.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (55)
- Feb 2, 2034method-of-use (U-2317)US 11266661
- Feb 2, 2034method-of-use (U-2317)US 11266661
- Nov 21, 2032method-of-use (U-2317)US 10258630
- Nov 21, 2032method-of-use (U-2317)US 10258630
- Nov 21, 2032method-of-use (U-2614)US 10398708
- Nov 21, 2032method-of-use (U-2614)US 10398708
- Nov 21, 2032method-of-use (U-2316)US 10471072
- Nov 21, 2032method-of-use (U-2316)US 10471072
- Nov 21, 2032formulationUS 10537581
- Nov 21, 2032formulationUS 10537581
- Nov 21, 2032method-of-use (U-2316)US 10568891
- Nov 21, 2032method-of-use (U-2317)US 10568891
- Nov 21, 2032method-of-use (U-2317)US 10668082
- Nov 21, 2032method-of-use (U-2316)US 10668082
- Nov 21, 2032formulationUS 10806697
- Nov 21, 2032formulationUS 10806697
- Nov 21, 2032method-of-use (U-2316)US 10835487
- Nov 21, 2032method-of-use (U-2317)US 10835487
- Nov 21, 2032method-of-use (U-2317)US 10888516
- Nov 21, 2032method-of-use (U-2317)US 10888516
- Nov 21, 2032formulationUS 11065197
- Nov 21, 2032formulationUS 11065197
- Nov 21, 2032formulationUS 11116717
- Nov 21, 2032formulationUS 11116717
- Nov 21, 2032formulationUS 11123283
- Nov 21, 2032formulationUS 11123283
- Nov 21, 2032method-of-use (U-2317)US 11241445
- Nov 21, 2032method-of-use (U-2316)US 11241445
- Nov 21, 2032method-of-use (U-2316)US 11246875
- Nov 21, 2032method-of-use (U-2317)US 11246875
- Nov 21, 2032formulationUS 11304959
- Nov 21, 2032formulationUS 11304959
- Nov 21, 2032method-of-use (U-2317)US 11351182
- Nov 21, 2032method-of-use (U-2317)US 11351182
- Nov 21, 2032method-of-use (U-2317)US 11497709
- Nov 21, 2032formulationUS 9180091
- Nov 21, 2032formulationUS 9180091
- Nov 21, 2032formulationUS 9289382
- Nov 21, 2032formulationUS 9289382
- Jul 4, 2030compositionUS 82319063.9y
- Jul 4, 2030compositionUS 82319063.9y
- Jul 4, 2030compositionUS 82319063.9y
- Jul 4, 2030compositionUS 82319063.9y
- Jul 4, 2030compositionUS 82319063.9y
- Jul 10, 2028compositionUS 97243101.9y
- Jul 10, 2028method-of-use (U-2086)US 97309001.9y
- Jul 10, 2028method-of-use (U-2086)US 97309001.9y
- Jul 10, 2028method-of-use (U-2086)US 97309001.9y
- Jul 10, 2028formulationUS 97309001.9y
- Jul 10, 2028method-of-use (U-2086)US 97309001.9y
- Jul 10, 2028formulationUS 98334191.9y
- Jul 10, 2028formulationUS 98334191.9y
- Jul 10, 2028formulationUS 98334191.9y
- Jul 10, 2028formulationUS 98334191.9y
- Jul 10, 2028formulationUS 98334191.9y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 37m ago
Found something off?
comments(0)
5-min edit window · permanent after that